0001336674-11-000001.txt : 20110218 0001336674-11-000001.hdr.sgml : 20110218 20110218130356 ACCESSION NUMBER: 0001336674-11-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20110218 DATE AS OF CHANGE: 20110218 EFFECTIVENESS DATE: 20110218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viamet Pharmaceuticals Inc CENTRAL INDEX KEY: 0001336674 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-80342 FILM NUMBER: 11623646 BUSINESS ADDRESS: STREET 1: 2250 PERIMETER PARK DRIVE STREET 2: SUITE 320 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-467-8539 MAIL ADDRESS: STREET 1: 2250 PERIMETER PARK DRIVE STREET 2: SUITE 320 CITY: MORRISVILLE STATE: NC ZIP: 27560 D/A 1 primary_doc.xml X0704 D/A LIVE 0001336674 Viamet Pharmaceuticals Inc 2250 PERIMETER PARK DRIVE SUITE 320 MORRISVILLE NC NORTH CAROLINA 27560 919-467-8539 DELAWARE Hephistics, Inc. None Corporation true Robert Schotzinger 2250 Perimeter Park Drive Suite 320 Morrisville NC NORTH CAROLINA 27560 Executive Officer Director James Rosen c/o Intersouth Partners VI, L.P. 406 Blackwell Street, Suite 200 Durham NC NORTH CAROLINA 27701 Director Douglas Reed c/o Hatteras Venture Partners III, LP 280 S. Mangum Street, Suite 350 Durham NC NORTH CAROLINA 27701 Director William T. White, III c/o Lurie Investment Fund, LLC 440 W. Ontario Street Chicago IL ILLINOIS 60610 Director Lauren Silverman c/o Novartis Option Fund Five Cambridge Center Cambridge MA MASSACHUSETTS 02142 Director S. Edward Torres c/o Lilly Ventures Fund I, LLC 115 West Washington Street, Suite 1680 Indianapolis IN INDIANA 46204 Director Neil Moore 2250 Perimeter Park Drive Suite 320 Morrisville NC NORTH CAROLINA 27560 Executive Officer Andrew von Eschenbach 163 Sarasota Circle South Montgomery TX TEXAS 77356 Director Pharmaceuticals Decline to Disclose 06 true 0001336674-09-000003 2009-06-23 true true false 0 24999997 24999997 0 false 7 0 0 0 Other than the payment of salaries and other compensation and benefits no officer, director, or promoter will receive any payments from the proceeds of this offering. false Viamet Pharmaceuticals Inc /Robert Schotzinger/ Robert Schotzinger CEO 2011-02-18